Modulating absorption and postprandial handling of dietary fatty acids by structuring fat in the meal: a randomized crossover clinical trial.


To cite this version:


HAL Id: inserm-00766661
http://www.hal.inserm.fr/inserm-00766661
Submitted on 18 Dec 2012

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Modulating absorption and postprandial handling of dietary fatty acids
by structuring fat in the meal: a randomized cross-over clinical trial

Cécile Vors, Gaëlle Pineau, Laure Gabert, Jocelyne Drai,
Corinne Louche-Pélissier, Catherine Defoort, Denis Lairon,
Michel Désage, Sabine Danthine, Stéphanie Lambert-Porcheron,
Hubert Vidal, Martine Laville, and Marie-Caroline Michalski

1 From INRA USC1362, CarMeN, Cardiovascular Metabolism Diabetes and Nutrition laboratory, F-69621 Villeurbanne, France (CV, MCM); INSA-Lyon, IMBL, F-69621 Villeurbanne, France (CV, MCM); Université de Lyon, F-69100 Villeurbanne, France (LG, CLP, MD); INSERM U1060, CarMeN, F-69921 Oullins, France (GP, HV); CRNH Rhône-Alpes, CENS, F-69921 Oullins, France (LG, JD, CLP, MD); INSERM UMR1062, Nutrition, Obesity and Risk of Thrombosis laboratory, F-13385, Marseille, France (CD, DL); INRA, UMR1260, F-13385 Marseille, France (CD, DL); Aix-Marseille Univ, Faculté de Médecine, F-13385 Marseille, France (CD, DL); Université de Liège, GxABT, Department of Food Science and Formulation, Gembloux, Belgique (SD); Hospices Civils de Lyon, F-69008 Lyon, France (JD, SLP); Laboratoire de Biochimie, Centre Hospitalier Lyon Sud (JD).

Authors’ last names: Vors, Pineau, Gabert, Drai, Louche-Pélissier, Defoort, Lairon, Désage, Danthine, Lambert-Porcheron, Vidal, Laville, Michalski.
This work was funded by the Centre National Interprofessionnel de l’Economie Laitière (CNIEL). CV received funding for PhD study by INRA and CNIEL. CV received a Research Prize from the Foundation Nestlé France. HV received financial support from Ezus-Lyon1. The funding agencies had no role in the data analysis.

Corresponding author, to whom reprints may be requested:
INRA U1235, Cardiovasculaire Métabolisme diabEtologie et Nutrition, CarMeN, Bâtiment IMBL, INSA-Lyon, 11 avenue Jean Capelle, 69621 VILLEURBANNE cedex, France
E-mail: marie-caroline.michalski@insa-lyon.fr
Phone: +33 4 72 43 81 12 - Fax: +33 4 72 43 85 24

Abbreviations: AMF: anhydrous milk fat; AP: atom percent; APE: atom percent excess; AUC: area under curve; iAUC: incremental area under curve; CMRF: chylomicron-rich fraction; CRNH-RA: Human Nutrition Research Center Rhône-Alpes; d32: volume-surface mean diameter; dARF: acetate recovery factor; DSC: differential scanning calorimetry; FA: fatty acid; FAMEs: fatty acid methyl esters; NEFA: non-esterified fatty acid; NW: normal-weight; TAG: triacylglycerol; XRD: X-ray diffraction.

Running title: Fat structuring modifies postprandial metabolism.

Clinical trial registry: Clinical Trials, #NCT01249378
ABSTRACT

Background: Prolonged postprandial hypertriglyceridemia is a potential risk factor for cardiovascular diseases. In the context of obesity, this is associated with a chronic imbalance of lipid partitioning oriented towards storage and not towards β-oxidation.

Objectives: We tested the hypothesis that the physical structure of fat in a meal can modify absorption, chylomicron transport and further metabolic handling of dietary fatty acids.

Design: 9 normal-weight and 9 obese subjects were fed 40 g of milkfat (+13C-triacylglycerols), either emulsified or not, in breakfasts of identical composition. We measured the postprandial triglyceride content and size of the chylomicron-rich fraction, plasma kinetics of 13C-fatty acids, exogenous lipid oxidation using breath-test/indirect calorimetry, and fecal excretion.

Results: The emulsified fat resulted in earlier (>1h) and sharper chylomicron and 13C-fatty acids peaks in plasma compared to spread fat in both groups (P<0.0001). After 2h, the emulsified fat increased ApoB48 concentration (9.7 ±0.7 vs 7.1 ±0.9 mg/L; P<0.05) in the normal-weight subjects compared to the spread fat. For the obese subjects, emulsified fat resulted in 3-fold larger chylomicrons (218 ±24 nm) compared to the spread fat (P<0.05). The emulsified fat induced higher dietary fatty acid spillover in plasma and sharper 13CO2 appearance, provoking increased exogenous lipid oxidation in each group: from 45% to 52% in normal-weight subjects (P<0.05), 40% to 57% in obese (P<0.01).

Conclusions: This study supports a new concept of “slow vs fast fat” whereby intestinal absorption can be modulated by structuring of dietary fat to modulate postprandial lipemia and lipid β-oxidation in humans of different BMI.

Key words: intestinal absorption; chylomicron; emulsion; stable isotopes; obesity.
INTRODUCTION

The metabolic importance of intestinal absorption and transport of nutrients in the postprandial period is recognized as important in the context of metabolic diseases such as obesity and type 2 diabetes (1). Regarding lipid metabolism, plasma kinetics, timing of peak of lipemia as well as chylomicron size are recognized as factors determining metabolic complications that are still an open field of research (2-4). For this reason, control of intestinal lipid absorption, the resulting chylomicron transport dynamics and ultimate dietary lipid fate may be an effective tool in the management of metabolic diseases. Recent studies have shown differential effects of oral sensory stimulation with high vs low amounts of dietary fat on intestinal lipid absorption (5). The possible effects of fatty acid (FA) profile of an oral fat load on chylomicron size have been suggested (6-10). While both fat load and composition can affect postprandial lipid absorption, few studies have investigated the effects of fat structure on the postprandial metabolism of an identical lipid load. In diabetes, the concept of “slow/low glycemic index carbohydrates and fast/high glycemic index carbohydrates” is well established and has facilitated the development of specific foods and/or cooking methods to control postprandial glycemia (11). We thus raised the question of whether a similar concept may be applicable to dietary fat according to the way it is structured in the meal.

Dietary lipids are incorporated in food products with different physicochemical structures, e.g., in dispersed lipid droplets in oil-in-water emulsions like ice cream or in a continuous lipid phase in butter and margarine. Emulsions are the most widespread fat structures, in processed foods and enteral formulas, and are therefore of interest regarding their role in lipid digestion and absorption (12). Indeed, we have previously demonstrated in rodents the importance of lipid emulsified structure on FA absorption and β-oxidation (13-15). However, the impact of fat structure on the kinetics of lipid absorption and dietary FA handling in humans remains to be elucidated. Such effects also deserve to be elucidated in obese subjects that present altered storage function of dietary FA in the postprandial state (16).
We therefore hypothesized that the physicochemical structure of the fat in a meal could modulate postprandial lipemia and fat partitioning: storage vs oxidation, and that the effect would be more pronounced in obese subjects. We investigated the metabolic response to fat-containing meals (40 g) differing only in the structuring of fat, emulsified or not, in healthy young normal weight and obese men. Measurements included chylomicron number and size, FA β-oxidation and FA excretion in feces. The aim of this study was to define the contribution of fat structure and subject BMI on the postprandial lipemia and metabolism of dietary FA.

SUBJECTS AND METHODS

Study design

The study was an open label trial with a cross-over randomized controlled design involving 2 days of metabolic testing separated by at least three weeks (Supplemental Figure 1). It was conducted at the Human Nutrition Research Center Rhône-Alpes (CRNH-RA; Lyon, France) according to the Second Declaration of Helsinki and the French Huriet-Serusclat law. The LIPINFLOX study was approved by the Scientific Ethics Committee of Lyon Sud-Est-II and AFSSAPS and registered at Clinical Trials (#NCT01249378). Volunteers received written and oral information and their medical history was reviewed. In addition they underwent a physical examination and fasting clinical analysis were assessed before enrolment. Informed written consent was obtained from all subjects. Volunteers performed trial in the period from April 2010 to July 2011. During the protocol, all subjects were asked to continue their regular diet and activity except for the week before and the 3-d period following each test day. Subjects were told to avoid foods naturally rich in $^{13}$C and were given a list. For 48 h prior to testing subjects were asked to refrain from consuming alcohol and to avoid exercise. In addition, subjects were provided with a standardized dinner.
the evening prior to testing. Compliance was checked through diet records, 5 days before and 3 days after each test day.

After an overnight of fast, subjects ingested one of the two test breakfasts. The primary outcome measured was the effect of fat structure on postprandial lipemia. Secondary outcomes measured were the effect of fat structure and BMI on postprandial lipid metabolism. Previous studies on lipemia (17) and lipid oxidation (18) were used for the power analysis: a minimum sample size of 8 subjects per BMI group was calculated to be necessary to detect significant changes in these parameters. The treatments were randomized according to a random allocation sequence performed by a CRNH-RA biostatistician using Stat® v.11; two randomization lists were generated and stratified over BMI. Subjects were anonymized using a number corresponding to randomization sequence order.

**Subjects**

Twenty-two healthy men were recruited, 11 normal-weight (NW) and 11 obese, and 20 completed the study (see Flow Diagram online). One subject in each group was not included in data analyses due to abnormal postprandial lipid metabolism; therefore 18 healthy subjects divided in two groups, 9 NW and 9 obese with comparable mean age were finally tested for the primary outcome, *(Table 1).* Volunteers were required to be non-smokers, sedentary or having <4h per week of physical activity and non-claustrophobic. We excluded persons under medication interfering with lipid metabolism, with psychological illness, or those with eating/metabolic disorders. In addition, subjects were required to have had stable weight, to be free of diabetes and to have not made blood donation for 3 months prior to the start of the study. Data were collected at CRNH-RA.
**Test meals**

The test breakfasts were isoenergetic, equal in nutrient composition (Table 2) and both consisted of bread (50 g), skimmed milk (160 mL) and anhydrous milk fat (AMF; 40 g), containing 600 mg of tracers, either spread on bread or emulsified in skim milk. Both meals had the same composition as no additional emulsifier was added because milk proteins are sufficient to provide a submicronic milk fat emulsion. Prior to the test day, a mixture of labeled triacylglycerols (TAG) proportionally representing each FA type present in test fat was first incorporated into melted milk fat: 300 mg of [1,1,1-$^{13}$C$_3$] tripalmitin for long-chain saturated FA, 210 mg of [1,1,1-$^{13}$C$_3$] triolein for unsaturated FA and 90 mg of [1,1,1-$^{13}$C$_3$] trioctanoin for short- and medium-chain FA (99 atom% $^{13}$C, Eurisotop, Saint-Aubin, France).

For the emulsion test, melted labeled milk fat was coarsly pre-mixed in skimmed milk (ProScientific Inc., Oxford, USA) and then further finely emulsified (4x 1 min, Vibra-cell$^\text{TM}$ Ultrasonic Processor, Sonics, Newtown, USA) (Supplemental Figure 2). Test products were then kept at 4°C overnight.

A second meal was served 5 hours after breakfast, containing pasta (200 g), turkey (100 g), butter (10 g), olive oil (10 g), bread (50 g), stewed fruit (100 g) which provided 713 kcal (2985 kJ) with 29%, 51% and 20% of energy as lipids (22.7 g), carbohydrates (91.5 g) and proteins (35.7 g) respectively. All subjects were given 10 minutes to eat breakfast and 30 minutes for lunch. During the test, participants were allowed to drink 200 mL of water.

**Test fat characterization**

Emulsion droplet size was measured by Dynamic Light Scattering (Zetasizer Nano S, Malvern, France). Specific surface area of emulsion droplets was calculated using Laser Light Scattering (Mastersizer 2000, Malvern, France). The melting temperature and crystalline state of the fat was characterized by Differential Scanning Calorimetry (DSC) using a Q1000 DSC.
(TA Instruments, New Castle, USA) and by powder X-ray Diffraction (XRD) using a D8 Advance diffractometer (Bruker, Germany).

**Hunger assessment**

Subjective assessment of hunger was measured on a 10-cm visual analogue scale 2 min before breakfast and 2 min before lunch. Specific question to assess hunger was “How hungry do you feel?”.

**Metabolic explorations**

Blood samples were obtained at baseline and at regular intervals after the meal, from an antecubital arm vein through a catheter and collected in vacutainer sterile tubes (with EDTA when necessary). Plasma was separated by centrifugation (1500 g, 10 min, 4°C) and stored at -20°C until analysis or at 4°C for separation of the chylomicron-rich fraction (CMRF).

Metabolic tests were divided into postprandial phases including a first period of 5 hours (0 to 300 min) post-breakfast in the morning, a second period of 3 hours post-lunch (300 to 480 min) and the entire exploration day (0 to 480 min).

Indirect calorimetry was performed during metabolic testing using a Deltatrac II™ calorimeter (Sensormedics, Yorba Linda, CA, USA). Respiratory exchanges (VO₂ and VCO₂) were recorded for periods of 30 or 60 minutes during the 8-h test period. Substrate oxidations were calculated using Ferrannini’s equations (19). Urine was collected at 0, 300 and 480 min to determine nitrogen excretion for oxidation calculations. For breath test, expired gas samples were obtained at baseline, each 30 min for 8-h and then at 720 and 1440 min to check return to baseline. Subjects had to collect and freeze their stools individually over 72 h after the test day.
Plasma metabolite and hormone measurements

Non esterified fatty acid (NEFA) concentrations were determined by an enzymatic method Wako® (Neuss, Deutschland). ApoB48 was measured by ELISA (Gentaur, France). Insulin concentration was determined by RIA (CISBio Bi insuline IRMA, France).

Isolation and analysis of chylomicron-rich fractions

To collect the CMRF, containing chylomicrons and their large remnants, 250 μL of plasma was deposited below a layer of 850 μL of distilled/deionized water and centrifuged at 80 000 rpm for 30 min using a Sorvall Kendro ultracentrifuge (Asheville, NC, USA). The floating layer was collected and stored at -80°C. TAG and cholesterol concentrations of CMRF were measured with a lipase glycerokinase and a cholesterol esterase/oxidase method, respectively, on a AU 2700 Beckman Coulter® (O’Cllagan’s mils, Ireland) and expressed as differences in concentration over baseline. Hydrodynamic diameter of CMRF was measured by dynamic light scattering at 25°C using a ZetaSizer NanoS (Malvern, UK) using 1.0658 cP and 1.33 as viscosity and refractive index of the aqueous phase, respectively. Gravity-separated fraction containing chylomicrons and their large remnants are reported to size in the range 70-450 nm (20-22), and postprandial increase in cholesterol content of such fraction is about <0.2 mM (23). Our fraction collected by ultracentrifugation contained particles of mean diameter up to 200-300 nm and with postprandial increase in cholesterol of <0.15 mM in NW and <0.25 mM in obese subjects. Our CMRF is thus typical of fractions that are rich in chylomicrons and that also contain large remnants.

$^{13}$C-fatty acids in plasma lipids, NEFA, CMRF and stools

Sample preparation. Internal standards were added according to the fraction analyzed (heptadecanoic acid or glycerol triheptadecanoate).
Plasma processing. Plasma samples were submitted to direct methylation as described previously (24).

NEFA processing. Total lipids were extracted from plasma aliquots at 120 min after breakfast consumption (700µL) with 3 mL of a mixture of chloroform/methanol (2:1 v/v) according to Folch method (25). NEFA fractions were obtained therefrom by TLC on silica-gel plates with a mobile phase of hexane/diethyl ether/acetic acid (80:20:1 v/v/v). NEFA were derivatized to Fatty Acid Methyl Esters (FAMEs) (24).

CMRF processing. Lipids were extracted from CMRF at 120 min after breakfast according to Folch method (25). TAG fractions were then processed as the NEFA fractions above, to obtain the FAMEs from CMRF.

Stool processing. Fecal collections were weighed, homogenized and a precisely weighed aliquot was collected. Total lipids were extracted according to a modification of the Folch method and derivatized to obtain FAMEs (24).

Sample analysis. The amounts of FA in stools, plasma and NEFA were assessed by GC/MS using a quadrupole mass spectrometer connected to a gas chromatograph (MS 5975 and GC6890, Agilent Technologies, Massy, France). The isotopic enrichment of palmitic and oleic acids was determined using GC/C/IRMS (Isoprime, GV Instruments, Manchester, UK)(24). The $^{13}$C enrichments were expressed as atom percent excess (APE). The plasma concentrations of non-esterified labelled palmitic and oleic acids (called $[^{13}\text{C-NEFA}$]) and non-esterified unlabelled palmitic and oleic acids (called $[^{12}\text{C-NEFA}$]) were also obtained from these analyses.

Calculations associated with apparent dietary fatty acid “spillover”

NEFA analysis at 120 min after breakfast was used to calculate $^{13}$C enrichment in plasma NEFA as: $[^{13}\text{C-NEFA}$] / ( $[^{13}\text{C-NEFA}$] + $[^{12}\text{C-NEFA}$] ) (expressed in % enrichment). The proportion of exogenous NEFA in total plasma NEFA, expressed in %, was estimated by the
ratio of the $^{13}$C enrichment in plasma NEFA to the $^{13}$C enrichment of corresponding FA in the ingested milk fat. The proportion of exogenous fatty acids in plasma that was present in non-esterified form in the sum of pools NEFA+CMRF was calculated as: $[^{13}$C-NEFA]_{plasma} / ([^{13}$C-NEFA]_{plasma} + [^{13}$C-FA]_{CMRF} _{plasma})$, where $[^{13}$C-FA]_{CMRF} _{plasma} is the plasma concentration of $^{13}$C-FA esterified in CMRF-TAG = $[^{13}$C-FA]_{CMRF} _{plasma} / ( [^{13}$C-FA]_{CMRF} _{plasma} + [^{12}$C-FA]_{CMRF} _{plasma} ) \times 3$ x $[^{13}$C-FA]_{CMRF} _{plasma} _{plasma}.

Calculations of exogenous lipid oxidation from indirect calorimetry & breath tests

Exogenous lipid oxidation was calculated according to Binnert et al. (18) from data of indirect calorimetry and breath tests. Here the formula was adapted to our use of 3 labeled triglycerides as follows:

$\text{Exogenous lipid oxidation (\% of ingested fat)} = \frac{\left(\frac{[AP \ CO_2(t)] + AP \ CO_2(t_0)}{2} - AP \ CO_2(t_0)\right) \times \frac{V \ CO_2}{100}}{\left(\frac{A}{100}\right) + \left(\frac{B}{100}\right) + \left(\frac{C}{100}\right)} \times 22.4 \times dARF \times 100$

With:

$A = \left(\frac{AP \^{13}TG \ C8:0}{100}\right) \times \left(\frac{0.09/473.66}{27}\right)$

$B = \left(\frac{AP \^{13}TG \ C16:0}{100}\right) \times \left(\frac{0.30/810.30}{51}\right)$

$C = \left(\frac{AP \^{13}TG \ C18:1}{100}\right) \times \left(\frac{0.21/888.40}{57}\right)$

Where $AP \ CO_2(t)$ is the AP value of the expired CO$_2$ at time t, $AP \ CO_2(t_0)$ is the AP value of the expired CO$_2$ at time $t_0$, AP tracers is the calculated AP value of the labeled mixture of TAG (tracers) and $V \ CO_2$ is the production rate of expired CO$_2$ (indirect calorimetry). Mean molecular weights of trioctanoin, tripalmitin and triolein are 473.66 g/mol, 810.30 g/mol and 888.40 g/mol, respectively. Mean number of carbons in trioctanoin, tripalmitin and triolein are 27, 51 and 57, respectively. $dARF$ (Acetate Recovery Factor) is the correction factor for
incomplete recovery of $^{13}$C bicarbonate (0.505 for NW; 0.453 for obese (26)) and 22.4 is the molar volume (L) of CO$_2$.

Kinetic parameters

We calculated the incremental area under curve (iAUC); maximum postprandial concentration, delta and diameter ($C_{\text{max}}$, $\Delta_{\text{max}}$, $d_{\text{max}}$); time for appearance of these maximum parameters ($t_{\text{max}}$) and appearance/enlargement-rates between 0 and 60 min.

Statistical analysis

Each subject served as his own control. All data are presented as means ±SEM ($n=9$ per group) and were analyzed with Statview 5.0 software (Abacus Concept, Berkeley, CA). Postprandial data were compared by analysis of variance (ANOVA) for repeated measures followed by post-hoc test (Fisher PLSD) for statistical effects of (i) time alone ($P_{\text{time}}$) over the first postprandial period (0-300min), (ii) meal alone ($P_{\text{meal}}$) independently of the time in the postprandial period and (iii) interaction of both factors, time and meal ($P_{\text{time}\times\text{meal}}$). Kinetic parameters were compared by two-way ANOVA followed by Fisher PLSD according to meal and BMI ($P_{\text{meal}}$, $P_{\text{BMI}}$, $P_{\text{meal}\times\text{BMI}}$) and time period before/after lunch ($P_{\text{meal}\times\text{BMI}\times\text{time}}$). Multiple comparisons regarding tracer excretion in feces were performed using ANOVA followed by Bonferroni post-hoc test. Comparisons between meals within subject groups were performed using a paired Student’s $t$-test and comparisons between subject groups within meals with an unpaired Student’s $t$-test. Differences were considered significant at the $P<0.05$ level.

RESULTS

Properties of emulsion vs spread fat

The emulsion droplet size (Table 3; Supplemental Figure 3) indicates the homogenization was effective in producing the emulsions. The emulsion had an approximately ~70000-fold
greater surface area than the spread fat. To control for the possibility that the different metabolic effects could be attributed to the fat melting properties, we measured melting profiles and crystalline structures in all conditions (with or without tracers, emulsified or not, Supplemental Figure 4). According to these analyses, the test fat differed only by their structure (Table 3).

Hunger feeling
At the end of the first postprandial period (0-300 min) just before lunch, normal-weight subjects felt similarly hungry regardless of breakfast type (Supplemental figure 5). In contrast, obese subjects felt hungrier after emulsion than spread fat ($P < 0.05$; Supplemental figure 5). Of note, before breakfasts, all subjects felt equally hungry (not shown).

Postprandial concentration profile and size of chylomicron-rich fraction
Figure 1A-B shows that in both groups, CMRF-TAG rapidly increased (60 min) after ingestion of emulsified fat and peaked at 3-4 h ($t_{\text{max}}$ in Table 4). The emulsion induced a significantly earlier and sharper increase in CMRF-TAG than the spread fat (Table 4: $t_{\text{max}}$ and appearance-rate$_{0-60\text{min}}$; $P < 0.001$). These differences were dramatically marked in the obese subjects, with a significant delay in absorption of the spread fat from 0 to 300 min compared to NW subjects ($P < 0.01$, Table 4). At the end of the test, CMRF-TAG of NW subjects returned to lower values regardless of fat structure. The obese subjects showed different profiles, with CMRF-TAG remaining elevated at the end of the spread fat test: e.g. at 480 min, $0.61 \pm 0.15$ mmol/L for spread vs $0.27 \pm 0.06$ mmol/L for emulsion above fasting baseline ($P < 0.05$). These differences in profile before and after lunch according to obese state and meal type are supported by different BMI x meal x time interactions for the $\Delta_{\text{max}}$ and iAUC of CMRF-TAG (Table 4).
Mean CMRF size sharply increased in both groups from the first hour after emulsion (Figure 1 C-D; \(P_{\text{meal}}<0.05\) for enlargement-rate0-60min, Table 4). For NW subjects, CMRF diameters were similar for spread fat and emulsion all along the test. In obese subjects, CMRF diameters became equal for both meals at 300 min. We can note that in the period from 0 to 240 min, CMRF diameter in obese subjects was higher after emulsion vs spread fat from 0 to 240 min (\(P_{\text{meal}}<0.05\) and \(P_{\text{time}}<0.001\)). Altogether, obese subjects presented larger CMRF than NW subjects (\(P<0.01\) for \(d_{\text{max}}\) 0-480 min, Table 4) with persistence of large CMRF after the second meal for spread fat.

**Plasma concentration profile of ApoB48**

Figure 1E-F shows that plasma ApoB48 changed over time in both groups after both breakfasts (\(P_{\text{time}}<0.0001\)) and differently according to the type of breakfast for NW subjects (\(P_{\text{time}}x\text{meal}=0.001\)). At 120 min, NW subjects accumulated more ApoB48 after consumption of emulsion than spread fat (7.08 ±0.86 mg/L for spread fat vs 9.73 ±0.69 mg/L for emulsion, \(P<0.05\)) and compared with obese subjects for emulsion (7.47 ±0.78 mg/L, \(P<0.05\)).

**Plasma concentration profile of \(^{13}\text{C}\)-fatty acid tracers and fecal loss**

Figure 2A-B-C-D shows a change in plasma \(^{13}\text{C}\)-palmitic and \(^{13}\text{C}\)-oleic acids over time in both groups after both breakfasts (\(P_{\text{time}}<0.0001\)). \(^{13}\text{C}\)-palmitic acid appeared earlier and sharper in plasma when it was in emulsion, differences between breakfasts being greater for obese (\(P_{\text{meal}}=0.007\)). Plasma concentrations of \(^{13}\text{C}\)-oleic acid were higher during 5h of emulsion digestion, especially for obese subjects (\(P_{\text{meal}}=0.018\) and \(P_{\text{time}}x\text{meal}=0.0002\)). For both tracers, a second peak was observed at 360 min, after ingestion of the second meal.

During the first 300 min for obese subjects, the iAUC for plasma \(^{13}\text{C}\)-FA were significantly higher after consumption of emulsion vs spread fat (\(P<0.05\), Figure 2B-D). iAUC after spread fat were lower for obese vs NW subjects (\(P<0.05\), Figure 2B-D).
Fecal excretion of $^{13}$C-palmitic acid was higher than that of $^{13}$C-oleic acid (Figure 2E). There was no effect of breakfast type on fecal excretion of $^{13}$C-palmitic acid or $^{13}$C-oleic acid in the two groups.

**Plasma concentration profile of insulin and NEFA and apparent dietary FA spillover**

*Figure 3A-B-C-D* shows a significant change in plasma insulin and NEFA over time after the two breakfasts in both groups ($P_{\text{time}} < 0.0001$). Over the first 300 min, the NEFA profile indicated a meal type x time interaction in both groups, with the decrease in plasma NEFA at 120 min being lower for emulsion than spread (Figure 3C-D). Therefore, we measured $^{13}$C enrichment in plasma NEFA at 120 minutes (Figure 3E) to estimate whether this would result from the contribution of exogenous FA, so-called apparent fatty acid “spillover”. We observed higher apparent “spillover” during the postprandial phase of emulsion vs spread fat, in both groups ($P < 0.05$ for NW and $P < 0.01$ for obese subjects, Figure 3E). The contribution of exogenous FA to total NEFA in NW subjects was 42% for spread vs 79% for emulsion, and was lower in obese, 4% for spread vs 50% for emulsion (meal effect, $P < 0.01$; BMI effect, $P < 0.01$; no meal x BMI interaction). Moreover, in NW subjects, the proportion of exogenous FA being in non-esterified form in plasma at 120 min was 10.6 % for spread vs 18.7 % for emulsion, i.e. 1.8-fold increase, and in obese 10.1 % for spread vs 15.0% for emulsion, i.e. 1.5-fold increase ($P < 0.05$ for spread vs emulsion; no significant effect of BMI nor meal x BMI interaction). In the same time emulsification increased total plasma NEFA by 2.2-fold in NW and by 1.6-fold in obese subjects (Figure 3C-D). Altogether, this means that more than 80 % of the increase of plasma NEFA due to emulsification may be explained by an increased amount of exogenous fatty acids being released non-esterified in plasma (spillover).
Postprandial appearance of label in expired CO₂

The ¹³C appearance in expired CO₂ represents the final product of FA β-oxidation. A significant change in APE occurred over time in both groups ($P_{\text{time}}<0.0001$; Figure 4A-B). In both groups, APE was higher after consumption of emulsion vs spread fat over the first 300 min, indicating improvement of dietary fat β-oxidation using emulsified form. APE returned to baseline after 720 min. An effect of BMI was also observed with higher appearance-rate 0-60min in NW than obese subjects ($P<0.01$; Table 4).

Inserts in Figure 4A-B show that AUC of expired ¹³CO₂ after 300 min for the emulsion was significantly higher than for spread fat in both groups ($P<0.01$ for NW subjects and $P<0.001$ for obese subjects). Besides, over 0 to 720 min, obese subjects presented higher AUC of expired ¹³CO₂ after consuming emulsion vs spread fat ($P<0.05$, Figure 4B insert). Altogether, the structuring of fat in the meal significantly affected the kinetic parameters of ¹³CO₂ air enrichment regardless of BMI while BMI affected AUC and appearance-rate 0-60min (Table 4).

Exogenous lipid fate

We studied the metabolic handling of exogenous lipids by evaluating the fractions of ingested lipids that have been either oxidized or lost in feces, and so estimated the remaining fraction stored in body pools. For the same quantity and composition of ingested fat, all subjects β-oxidized FA better when fat was emulsified (Figure 4C). In turn, the calculated fraction of ingested lipids oriented towards storage in body pools was lower after emulsion vs spread consumption. After accounting for the part of exogenous lipids lost in feces (Figure 4C), the percentage of exogenous lipid oxidation according to the fraction that has been intestinally absorbed was higher for NW and obese subjects after emulsion vs spread fat ($P<0.05$ and $P<0.01$, respectively, Figure 4D). Total lipid oxidation was unchanged with the two
test meals in both groups but with a greater relative contribution of exogenous lipids ingested at breakfast as emulsion vs spread fat (Figure 4E).

**DISCUSSION**

Postprandial triglyceridemia is the first step in the metabolism of dietary lipids. Ingested FA are firstly present in plasma TAG in the form of intestinally secreted chylomicrons, which further lead to large remnants after hydrolysis by lipoprotein lipase (10, 22). The next step concerns trafficking of FA towards β-oxidation or storage that is of utmost importance regarding the metabolic impact of these dietary FA. We therefore investigated whether structuring fat in the meal could modify postprandial lipid metabolism, from the amount and size of chylomicrons to β-oxidation, including fecal loss. To this aim, labeled breakfasts containing either spread or emulsified fat were fed to NW and obese subjects. Test meals were designed to be of equal composition. Thus, factors like FA composition or protein content cannot be involved in the presently observed differences in lipid metabolism, which can be uniquely attributed to the fat physico-chemical structure in the meal. The postprandial chylomicron TAG profile after emulsion consumption differed from that of the spread fat, with the peak being more rapidly achieved, more pronounced and more quickly cleared, especially in obese subjects. This is consistent with reports of enhanced FA absorption when a simple bolus of vegetable oil was emulsified in humans (27) and rodents(14, 15, 28). One explanation is that our emulsion had ~70000-times greater surface area available for lipases than spread fat, which is reported to enhance lipolysis and absorption (29). Enteral emulsions of different droplet sizes, ~1 vs ~10 µm (14.5-fold difference in fat surface area), were shown to result in small differences only in postprandial lipemia in humans (17). The dramatic differences observed in the present work are due to the greatest differences in fat structure. Of note, postprandial lipid metabolism was previously found faster using unemulsified than emulsified milk fat in rats (14). Differences with the present results can be explained by (i)
rodent physiology of bile flow that is different from humans (30), and (ii) unemulsified melted milk fat being force-fed intragastrically, prior to the proteinaceous phase. This could have favored lipid emptying in the upper intestine and a rapid rise of plasma TAG in rats. Our study also provides a proof of concept that effects of fat structure in the meal can occur in a real mixed meal, while previous studies used oil or emulsion bolus fed orally or intragastrically (17, 29). Regarding emulsifier type, our fat was emulsified by the proteins naturally present in skim milk. Emulsions stabilized with caseins and monoacylglycerols were recently reported to result in lower postprandial plasma TAG than those formulated with lecithin in non-obese humans (31), which can be explained by lower in vitro digestive lipolysis (32). Because obese men were the most affected by emulsification, further work should test the effect of emulsifiers on postprandial lipid metabolism. The importance of sensory exposure to lipids on postprandial metabolism in humans was also recently revealed (5). Therefore, we cannot exclude a contribution of oral fat perception in our results.

TAG-rich lipoproteins remaining elevated all along the postprandial phase are an independent CVD risk factor (3, 4), which can be mechanistically related to the atherogenic potential of small chylomicron remnants (21, 22). In this study, we collected CMRF fractions containing chylomicrons and their large remnants. The latter do not contribute significantly to the formation of small atherogenic remnants because of direct hepatic clearance (33). However, the role of TAG-rich particles is still debated, underlining that this is still an open field needing further studies (1, 2). In this context, our study shows for the first time in NW and obese men that postprandial lipemia profile can be modulated by structuring the fat in a mixed meal. Therefore, the study of atherogenic small particles in the postprandial phase after consumption of differently structured lipids in the meal should now be performed.

Obese men presented a delayed increase of CMRF-TAG after spread fat. Overweight men were also reported to present delayed TAG-rich lipoprotein metabolism after a high-fat load (34). Our observed differences between the two breakfasts in obese men could be explained
by their lower pancreatic secretion and lower levels of gallbladder emptying compared with
lean men (35). Therefore, obese subjects can better hydrolyze fat when it is pre-emulsified.
Moreover, fine stable emulsions were reported to be emptied faster and to cause greater
release of cholecystokinin than those that broke and layer in the stomach (36, 37). We can
thus suggest that the fat absorption delay observed with spread fat can be due to layering in
the stomach and thus delayed emptying. Of note, immediately after lunch, a peak of $^{13}$C-FA
appeared in plasma. This so-called “second-meal effect” is known as the contribution of lipids
from a meal to lipemia after the next meal (38). For obese men, the marked delay in lipemia
appearance after spread fat cumulated with the second meal effect, causing high lipemia until
the test ended. In contrast, obese subjects (without fasting hyperlipidemia herein) did not have
difficulties in absorbing the emulsion, with a final return of lipemia to baseline.

In NW subjects, higher CMRF-TAG after the emulsion corresponded transiently to an
increased number of particles, as shown by the similar CMRF-size with an increased ApoB48
level at 120 min. In obese subjects however, ApoB48 levels remained similar, i.e., the
increase in lipemia after emulsion was due to an increased CMRF size. High particle numbers
estimated by ApoB48 level are reported to lead to increased chylomicron remnant numbers,
hence potentially increased atherosclerotic risk (10, 21). It would now be useful to explore the
chronic metabolic impact of fat structure, especially regarding ApoB48-containing particles.

The few reports about metabolic effects of emulsions have solely studied lipemia or
plasma FA concentrations as endpoints. For the first time to our knowledge, our study shows
that fat emulsification further affects the metabolic handling of exogenous FA, including β-
oxidation. Early appearance of $^{13}$CO$_2$ was due to the rapid β-oxidation of short-chain FA that
are directly absorbed in the portal vein and oxidized by the liver (39). Obesity is associated
with a defect in the β-oxidation of dietary FA (18, 40-42). Hodson et al. recently challenged
this idea by showing greater FA β-oxidation in obese men and attributed this to specific FA
acid partitioning (43). We highlight that exogenous FA oxidation can be enhanced in obese
men by emulsifying fat. Discrepancies between reports can thus be explained by the present “fast vs slow lipid” notion. Indeed, lower β-oxidation in obese vs lean subjects was observed using a single oil bolus (18) whereas higher β-oxidation in obese was observed when the tracer was dispersed into an emulsion (43). This aspect had not been taken into account by previous authors. Moreover, emulsification is now advised to enhance the intestinal absorption of essential fatty acids (27). However, our results highlight the risk that such essential FA quickly absorbed can be lost in the β-oxidation process rather than being bioavailable for cell membrane turnover. Therefore, further studies on the structuring of oils rich in essential PUFA should now investigate their final postprandial metabolic fate.

The effect of emulsification on exogenous lipid oxidation cannot be due to differences in intestinal absorption because of similar fecal excretion. Total lipid oxidation during the test day was unchanged by fat structuring, as well as total energy expenditure and diet-induced thermogenesis. However, the source of β-oxidized FA was different: using emulsion, exogenous FA ingested at breakfast were shunted towards β-oxidation pathways. Using spread fat, more endogenous FA and/or exogenous FA ingested at lunch were oxidized so that exogenous FA ingested at breakfast were more oriented towards storage. Therefore, regardless of energy balance, FA metabolism is changed by lipid structure. This is consistent with the greater FA spillover after emulsion. It can be explained by the faster intestinal absorption, resulting in enhanced lipolysis of chylomicrons that generates exogenous NEFA (44). Their early influx can serve as fuel for tissues and explain their higher contribution to total FA oxidation with emulsion. However, high NEFA can also constitute a risk for ectopic fat accumulation (44). Another aspect in obesity research concerns energy balance and satiety regulation (45, 46). Just before lunch, our obese subjects felt hungrier after emulsion than spread fat (visual analog scales, Supplemental figure 5). Further trials could test the impact of fat structuring at breakfast on satiety regulation at lunch and energy balance.
In summary, we demonstrate that the postprandial metabolic handling of dietary FA can be significantly modified by emulsifying the fat in the meal, especially in obese subjects. The clinical perspectives of this first study should thus not be underrated. This study supports the further exploration of a possible dietary concept of “fast vs slow lipid” for the nutritional management of metabolic diseases through food formulation. Our results in the postprandial phase raise the questions of whether (i) daily ingestion of “fast vs slow fat” would result in different lipid metabolisms, adiposity and/or cardiovascular risk markers in the long term and (ii) the composition and structuring of dietary lipids could be optimized to this aim.

Acknowledgements

We thank volunteers for their involvement. J Peyrat, C Maitrepierre, N Torche are acknowledged for technical assistance, M Sothier for dietary survey analysis, and C Louche-Pelissier, A Faure, M Cervantes, C Norbert and S Gonin for management of lipid analyses. B Morio, JM Antoine, C Boyer and C Marmonier are acknowledged for useful discussions. We thank RJ Ward for editing the English language. F Bellisle is acknowledged for advice on visual analog scales for hunger responses. Corman SA (N Vaghefi) is acknowledged for kindly providing AMF, Lactalis R&D (P Le Ruyet) for providing skimmed milk powder, and Sodiaal-Candia R&D (O Cousin, G Vialaret) for preparing and processing bottled flavoured skimmed milk.

The authors’ responsibilities were as follows — CV: designed research, conducted research, analyzed data, wrote paper, statistical analysis; GP: conducted research, technical support; LG: conducted research, technical support, analyzed data; JD: conducted research, technical and material support, analyzed data; CLP: conducted research, technical support; CD: acquisition of data, technical support; DL: critical revision of the manuscript for important intellectual content; MD: conducted research, analyzed data; SD: technical support, analyzed
data; SLP: designed research, administrative support; HV: critical revision of the manuscript for important intellectual content; ML: critical revision of the manuscript for important intellectual content; MCM: designed research, study supervision, analyzed data, wrote paper, had primary responsibility for final content. All authors read and approved the final manuscript. No conflict of interest exists for this manuscript.
REFERENCES


Table 1. Anthropometric and fasting metabolic subject parameters.

<table>
<thead>
<tr>
<th></th>
<th>Normal weight ( (n=9) )</th>
<th>Obese ( (n=9) )</th>
<th>( P ) value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anthropometric parameters</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>28.3 ± 1.4</td>
<td>30.2 ± 2.2</td>
<td>ns</td>
</tr>
<tr>
<td>Body weight (kg)</td>
<td>72.0 ± 2.1</td>
<td>101.2 ± 1.9</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>BMI (kg.m(^{-2}))</td>
<td>22.3 ± 0.5</td>
<td>31.7 ± 0.3</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>83.3 ± 1.6</td>
<td>105.9 ± 0.8</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td><strong>Fasting metabolic parameters</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose (mM)</td>
<td>4.94 ± 0.16</td>
<td>5.19 ± 0.15</td>
<td>ns</td>
</tr>
<tr>
<td>Insulin (mIU/L)</td>
<td>3.75 ± 0.59</td>
<td>7.14 ± 0.95</td>
<td>0.008</td>
</tr>
<tr>
<td>HOMA</td>
<td>0.85 ± 0.14</td>
<td>1.69 ± 0.25</td>
<td>0.009</td>
</tr>
<tr>
<td>Total cholesterol (mM)</td>
<td>4.85 ± 0.22</td>
<td>4.89 ± 0.24</td>
<td>ns</td>
</tr>
<tr>
<td>HDL cholesterol (mM)</td>
<td>1.51 ± 0.10</td>
<td>1.09 ± 0.06</td>
<td>0.004</td>
</tr>
<tr>
<td>LDL cholesterol (mM)</td>
<td>3.03 ± 0.27</td>
<td>3.11 ± 0.21</td>
<td>ns</td>
</tr>
<tr>
<td>Triacylglycerols (mM)</td>
<td>0.85 ± 0.06</td>
<td>1.39 ± 0.18</td>
<td>0.017</td>
</tr>
</tbody>
</table>

Data are means ± SEM. Groups are compared using unpaired Student’s \( t \)-test.
Table 2. Nutritional composition of the test breakfasts containing either spread or emulsified fat enriched with $^{13}$C-labelled triglycerides.

<table>
<thead>
<tr>
<th>Breakfast composition$^1$</th>
<th>Quantity (g or mL)</th>
<th>Carbohydrates (g)</th>
<th>Proteins (g)</th>
<th>Lipids (g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anhydrous Milk Fat$^2$</td>
<td>40</td>
<td>-</td>
<td>-</td>
<td>40</td>
</tr>
<tr>
<td>Skimmed milk$^3$</td>
<td>160</td>
<td>7.5</td>
<td>5.3</td>
<td>0.3</td>
</tr>
<tr>
<td>Bread</td>
<td>50</td>
<td>28</td>
<td>4</td>
<td>0.5</td>
</tr>
<tr>
<td>$[1,1,1-^{13}C_3]$ trioctanoin</td>
<td>0.09</td>
<td>-</td>
<td>-</td>
<td>0.09</td>
</tr>
<tr>
<td>$[1,1,1-^{13}C_3]$ tripalmitin</td>
<td>0.30</td>
<td>-</td>
<td>-</td>
<td>0.30</td>
</tr>
<tr>
<td>$[1,1,1-^{13}C_3]$ triolein</td>
<td>0.21</td>
<td>-</td>
<td>-</td>
<td>0.21</td>
</tr>
<tr>
<td>Total (g)</td>
<td>250.6</td>
<td>35.5</td>
<td>9.3</td>
<td>41.4</td>
</tr>
<tr>
<td>% caloric intake</td>
<td>26</td>
<td>7</td>
<td>67</td>
<td></td>
</tr>
</tbody>
</table>

$^1$ Identical nutrient composition for both spread and emulsion breakfasts.

$^2$ Fatty acid profile of TAG includes 68.6% SFA, 28.1% MUFA and 3.3% PUFA.

$^3$ Natural vanillia-flavoured.
Table 3. Physico-chemical properties of fat used in the formulation of test breakfasts.

<table>
<thead>
<tr>
<th>Structure (type of breakfast)</th>
<th>Fat properties&lt;sup&gt;1&lt;/sup&gt;</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Droplet size&lt;sup&gt;2&lt;/sup&gt;</td>
<td>d&lt;sub&gt;32&lt;/sub&gt;&lt;sup&gt;3&lt;/sup&gt;</td>
<td>Fat surface area in meal&lt;sup&gt;4&lt;/sup&gt;</td>
<td>Melting temperature&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>Spread</td>
<td>-</td>
<td>-</td>
<td>0.006</td>
<td>42</td>
</tr>
<tr>
<td>Emulsion</td>
<td>1.04</td>
<td>0.63</td>
<td>410</td>
<td>40</td>
</tr>
</tbody>
</table>

<sup>1</sup>Mixture of milk fat + <sup>13</sup>C-TAG tracers.

<sup>2</sup>Diameter of the peak of maximum intensity measured by DLS.

<sup>3</sup>Surface averaged diameter measured by LLS.

<sup>4</sup>For Spread fat: calculated as the surface of an equivalent sphere of 40 g. For Emulsion: calculated from the specific surface area (m<sup>2</sup> per g fat) calculated by the software, further multiplied by fat content in the meal.

<sup>5</sup>Temperature at which the entire fat amount is in liquid form.
Table 4. Kinetic parameters after digestion of test breakfasts in NW vs obese subjects.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Spread fat 40 g</th>
<th>Emulsified fat 40 g</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Normal-weight</td>
<td>Obese</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Normal-weight</td>
<td>Obese</td>
</tr>
<tr>
<td>Δ CMRF TAG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ΔAUC (%.min)</td>
<td>0.63 ± 0.13</td>
<td>0.80 ± 0.12</td>
<td>0.75 ± 0.09</td>
</tr>
<tr>
<td>iAUC (mmol-min/L)</td>
<td>132.8 ± 29.1</td>
<td>165.6 ± 23.1</td>
<td>180.4 ± 28.2</td>
</tr>
<tr>
<td>t_max (min)</td>
<td>293 ± 23</td>
<td>367 ± 33</td>
<td>220 ± 42</td>
</tr>
<tr>
<td>Appearance-rate&lt;sub&gt;0-40 min&lt;/sub&gt; (µmol/L/min)</td>
<td>0.32 ± 0.27</td>
<td>0.14 ± 0.32</td>
<td>2.85 ± 0.72</td>
</tr>
</tbody>
</table>

|                                  |                 |                     |         |
|                                  |                 | Normal-weight      | Obese  |
|                                  |                 | Normal-weight      | Obese  |
| 0-480 min:                       |                 |                     |         |
| ΔAUC (mmol/L)                   | 0.56 ± 0.10     | 0.53 ± 0.09         | 0.74 ± 0.09 | 0.94 ± 0.25 | 0.05     | ns       | ns       |
| iAUC (mmol-min/L)               | 81.4 ± 18.2     | 57.6 ± 10.7         | 127.7 ± 17.4 | 159.3 ± 39.6 | < 0.01   | ns       |         |
| t_max (min)                     | 233 ± 16        | 267 ± 15            | 167 ± 17  | 193 ± 17     | <0.0001  | < 0.1   | ns       |

|                                  |                 |                     |         |
|                                  |                 | Normal-weight      | Obese  |
|                                  |                 | Normal-weight      | Obese  |
| 0-300 min:                       |                 |                     |         |
| ΔAUC (mmol/L)                   | 0.54 ± 0.13     | 0.80 ± 0.12         | 0.54 ± 0.11 | 0.56 ± 0.14 | ns       | ns       | ns       |
| iAUC (mmol-min/L)               | 51.4 ± 12.9     | 107.9 ± 17.7        | 52.7 ± 11.2 | 58.8 ± 14.7 | < 0.05   | ns       | < 0.01  |
| t_max (min)                     | 347 ± 5         | 390 ± 23            | 397 ± 19  | 420 ± 24     | < 0.05   | < 0.1   | < 0.1   |

|                                  |                 |                     |         |
|                                  |                 | Normal-weight      | Obese  |
|                                  |                 | Normal-weight      | Obese  |
| 0-480 min:                       |                 |                     |         |
| d_max (mm)                       | 253 ± 34        | 494 ± 93            | 262 ± 20  | 344 ± 58     | ns       | < 0.01  | ns       |
| iAUC (mmol-min/L)               | 243 ± 25        | 307 ± 23            | 207 ± 30  | 237 ± 33     | < 0.1    | 0.1     | ns       |
| t_max (min)                     | -0.06 ± 0.07    | -0.02 ± 0.11        | 0.65 ± 0.11 | 1.26 ± 0.78 | < 0.05   | ns       | ns       |

|                                  |                 |                     |         |
|                                  |                 | Normal-weight      | Obese  |
|                                  |                 | Normal-weight      | Obese  |
| 0-300 min:                       |                 |                     |         |
| d_max (mm)                       | 246 ± 35        | 296 ± 70            | 239 ± 12  | 336 ± 58     | ns       | < 0.1   | ns       |
| iAUC (mmol-min/L)               | 180 ± 17        | 200 ± 41            | 200 ± 26  | 193 ± 28     | ns       | ns       | ns       |

|                                  |                 |                     |         |
|                                  |                 | Normal-weight      | Obese  |
|                                  |                 | Normal-weight      | Obese  |
| 0-480 min:                       |                 |                     |         |
| d_max (mm)                       | 195 ± 10        | 451 ± 96            | 207 ± 28  | 236 ± 46     | < 0.1    | < 0.05  | < 0.05  | 0.055   |
| iAUC (mmol-min/L)               | 337 ± 4         | 367 ± 17            | 340 ± 5  | 360 ± 16     | ns       | < 0.05  | ns       |         |

|                                  |                 |                     |         |
|                                  |                 | Normal-weight      | Obese  |
|                                  |                 | Normal-weight      | Obese  |
| 0-720 min:                       |                 |                     |         |
| C<sub>max</sub> (%)             | 0.019 ± 0.001   | 0.013 ± 0.001       | 0.019 ± 0.001 | 0.016 ± 0.001 | < 0.01   | ns       | ns       |
| AUC (%.min)                     | 6.9 ± 0.5       | 4.8 ± 0.8           | 7.7 ± 0.2  | 6.4 ± 0.5     | < 0.01   | < 0.001  | ns       |
| t_max (min)                     | 310 ± 21        | 347 ± 23            | 267 ± 26  | 267 ± 17     | < 0.01   | ns       | < 0.05  |
| Appearance-rate<sub>0-60 min</sub> (%/min) | 6.0 ± 0.001 | 2.0 ± 0.001 | 13.6 ± 0.001 | 9.8 ± 0.001 | < 0.0001 | < 0.0001 | < 0.0001 |
|                                  | ±1.7 ± 0.001   | ±0.5 ± 0.001        | ±1.9 ± 0.001 | ±0.8 ± 0.001 | < 0.0001 |         |         |

|                                  |                 |                     |         |
|                                  |                 | Normal-weight      | Obese  |
|                                  |                 | Normal-weight      | Obese  |
| 0-300 min:                       |                 |                     |         |
| C<sub>max</sub> (nmol/L)         | 0.018 ± 0.001   | 0.011 ± 0.001       | 0.019 ± 0.001 | 0.016 ± 0.001 | < 0.05   | < 0.0001 | < 0.05  |
| AUC (%.min)                     | 2.9 ± 0.3       | 1.6 ± 0.4           | 3.9 ± 0.2  | 3.2 ± 0.2     | < 0.0001 | < 0.0001 | ns       |
| t_max (min)                     | 283 ± 17        | 293 ± 7             | 257 ± 23  | 260 ± 14     | < 0.1    | ns       | ns       |

|                                  |                 |                     |         |
|                                  |                 | Normal-weight      | Obese  |
|                                  |                 | Normal-weight      | Obese  |
| 0-720 min:                       |                 |                     |         |
| C<sub>max</sub> (nmol/L)         | 0.019 ± 0.001   | 0.013 ± 0.001       | 0.019 ± 0.001 | 0.016 ± 0.001 | < 0.05   | < 0.0001 | < 0.05  |
| AUC (%.min)                     | 3.9 ± 0.4       | 3.2 ± 0.5           | 3.8 ± 0.3  | 3.1 ± 0.4     | < 0.1    | ns       | ns       |
| t_max (min)                     | 333 ± 3         | 360 ± 18            | 330 ± 0   | 330 ± 0       | < 0.1    | ns       | ns       |

Data are means ± SEM, n=9 per group. Calculated over the indicated time period: C<sub>max</sub> indicates maximum concentration; d<sub>max</sub> indicates maximum diameter; Δ<sub>max</sub> indicates maximum concentration delta; iAUC, incremental area under the curve; AUC, area under the curve. P values (P<sub>meal</sub>, P<sub>BMI</sub> and P<sub>meal*BMI</sub>) obtained by ANOVA followed by post hoc Fisher PLSD. 1 P values of two-way ANOVA for meal and BMI effects and their interactions. 2 P values of two-way ANOVA for repeated measures regarding both time periods (before and after 300 min), for meal x BMI x time period interactions.
Figure Caption

**Figure 1.** Postprandial profile after consuming spread fat (□, ■) or emulsion (○, ●): CMRF-TAG (mM) in NW (A) and obese subjects (B) and corresponding iAUC; CMRF size (nm) in NW (C) and obese subjects (D); ApoB48 (mg/L) in NW (E) and obese subjects (F). Data are means ±SEM, n=9 per group; \( P_{\text{time}} \), \( P_{\text{meal}} \) and \( P_{\text{time} \times \text{meal}} \) for postprandial period from 0 to 300 min (repeated measures-ANOVA followed by post-hoc Fisher PLSD).

(B) ** \( P < 0.01 \) for time 420 min emulsion vs spread fat (paired Student’s \( t \)-test); * \( P < 0.05 \) for emulsion vs spread fat at time 480 min and for iAUC\(_{0-300} \) (paired Student’s \( t \)-test); § \( P < 0.05 \) for obese vs NW regarding spread fat iAUC\(_{300-480} \) (unpaired Student’s \( t \)-test).

(D) * \( P < 0.05 \) for time 120 min emulsion vs spread fat (paired Student’s \( t \)-test)

(C-D) §§ \( P < 0.01 \) for time 120 min obese vs NW subjects (unpaired Student’s \( t \)-test);

(E-F) * \( P < 0.05 \) for time 120 min emulsion vs spread fat (paired Student’s \( t \)-test), § \( P < 0.05 \) for time 120 min obese vs NW subjects (unpaired Student’s \( t \)-test).

**Figure 2.** Postprandial concentration profile and iAUC of total plasma lipids of \(^{13}\text{C}\)-palmitic acid (mM) and \(^{13}\text{C}\)-oleic acid (mM) in NW (A & C, respectively) and obese subjects (B & D, respectively) consuming spread fat (□, ■) or emulsion (○, ●). (E) Fecal excretion of \(^{13}\text{C}\)-palmitic acid and \(^{13}\text{C}\)-oleic acid in NW (white bars) and obese subjects (black bars) consuming spread fat (plain bars) or emulsion (droplet pattern bars).

Data are means ±SEM, n=9 per group.
(A-B-C-D) \( P_{\text{time}}, P_{\text{meal}} \) and \( P_{\text{time}\times\text{meal}} \) for postprandial period from 0 to 300 min (repeated measures-ANOVA followed by post-hoc Fisher PLSD).

(A-B) \(*P< 0.05\) for obese iAUC 0-300 min emulsion vs spread fat (paired Student’s \( t \)-test),

\( ^\S P< 0.05\) for spread fat iAUC 0-300 min obese vs NW subjects (unpaired Student’s \( t \)-test),

\( ^\S P< 0.1\) for obese iAUC 0-480 min emulsion vs spread fat (paired Student’s \( t \)-test); (C-D)

\(*P< 0.05\) for obese iAUC 0-300 min emulsion vs spread fat (paired Student’s \( t \)-test),

\( ^\S P< 0.05\) for spread fat iAUC 0-300 min obese vs NW subjects (unpaired Student’s \( t \)-test); (E) no common letter with another bar indicates a statistical difference, \( P< 0.001\) (ANOVA followed by post-hoc Bonferroni).

**Figure 3.** Postprandial concentration profile of insulin (mU/L) and NEFA (\( \mu \)M) in NW (A & C, respectively) and obese subjects (B & D, respectively) consuming spread fat (□, ■) or emulsion (○, ●). (E) \(^{13}\)C-enrichment of plasma NEFA at 120 min, estimating so-called apparent fatty acid “spillover” in NW (white bars) and obese subjects (black bars) consuming spread fat (plain bars) or emulsion (droplet pattern bars).

Data are means \( \pm \)SEM, \( n=9\) per group; \( P_{\text{time}}, P_{\text{meal}} \) and \( P_{\text{time}\times\text{meal}} \) for postprandial period from 0 to 300 min (repeated measures-ANOVA followed by post-hoc Fisher PLSD).

(C) \(*^\S P< 0.01\) for NW subjects at 120 min emulsion vs spread fat (paired Student’s \( t \)-test);

(D) \(*P< 0.05\) for obese subjects at 120 min emulsion vs spread fat (paired Student’s \( t \)-test);

(E) \(*P< 0.05\) for NW subjects at 120 min emulsion vs spread fat (paired Student’s \( t \)-test);

\(*^\S P< 0.01\) for obese subjects at 120 min emulsion vs spread fat (paired Student’s \( t \)-test);

ANOVA analysis revealed meal effect \( (P<0.01)\) and BMI effect \( (P<0.01)\) but no significant meal x BMI interaction.
**Figure 4.** Postprandial profile of $^{13}$C-appearance in breath in NW subjects (A) and obese subjects (B) consuming spread fat (□, ■) or emulsion (○, ●); (C) Exogenous lipid fate, either oxidized (white), lost in feces (black) or stored (grey, calculated as “total – (lost+oxidized)” in NW and obese subjects over 480 min; (D) Oxidation of intestinally absorbed lipids over 480 min in NW (white bars) and obese subjects (black bars) consuming spread fat (plain bars) or emulsion (droplet pattern bars); (E) Total lipid oxidation (total bar) and fraction of cumulative exogenous lipid oxidation (dashed part) over 480 min after consuming test breakfasts in NW vs obese subjects.

Data are means ±SEM, n=9 per group.

(C-D-E) * $P<0.05$ for NW subjects and ** $P<0.01$ for obese subjects emulsion vs spread fat (paired Student’s $t$-test). ANOVA analysis revealed no significant meal x BMI interaction ($P=0.087$).